<DOC>
	<DOCNO>NCT02587988</DOCNO>
	<brief_summary>Trial Evaluate Efficacy Safety HCP1302</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety HCP1302</brief_title>
	<detailed_description>A Randomized , Double-blind , Multicenter , Phase Ⅲ study Evaluate Efficacy Safety HCP1302 Both Erectile Dysfunction Hypertension Patients Treated HGP0904</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>At Visit1 1 . ≥19 age 2 . Hypertension Patients need amlodipine 5mg 3 . Abnormal Erectile function ≥ least 3months base screening date 4 . Patients expect frequent use Tadalafil ( least two time week ) 5 . Patients understood consent purpose trial sign informed consent form At Visit2 1 . 90≤ sitSBP &lt; 140 mmHg 50 ≤ sitDBP &lt; 90 mmHg 2 . Sexual dysfunction rate ≥ 50 % 4 week runin period 3. International Index Erectile Function ( IIEF ) Erectile Function ( EF ) domain score ≤ 25 1 . History hypersensitivity Amlodipine Tadalafil 2 . Has severe liver disorder ( ChildPugh Class C ) liver enzyme ( AST , ALT ) level exceed 3 time normal upper range 3 . Has clinically significant renal failure ( Scr &gt; 2mg/dl ) 4 . Uncontrolled diabetes mellitus ( HbA1C &gt; 12 % ) 5 . At screen date , blood pressure gap select arm sitSBP ≥20mmHg sitDBP ≥10mmHg 6 . Taking PDE5 inhibitor therapeutic agent Erectile Dysfunction within 7 day base screen date 7 . No reaction PDE5 inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Erectile dysfunction &amp; Hypertension</keyword>
</DOC>